It has been demonstrated that the detection of AMA and PBC-specific ANA were correlated with disease severity, while the autoantibody titers did not vary significantly during follow-up; this suggests that AMA and PBC-specific ANA are stably autoantibodies that are not influenced by UDCA treatment.[6] Furthermore, the sustained antibody response to gp210 was closely associated with the severity of interface hepatitis, in which anti-gp210 titers were sustained at high levels, and in which anti-gp210 status changed from positive to negative under UDCA therapy.[4]. The gene discussed is NUP210; the disease is primary biliary cholangitis.